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According to the World Health Organi-
zation [1], cardiovascular diseases are the 
leading cause of premature death world-
wide, with ischemic heart diseases, espe-
cially acute coronary syndrome (ACS), 
being a major cause [2]. Since a highly ef-
fective and evidence-based therapy con-
sisting of electrocardiogram (ECG) mon-
itoring, antiplatelet therapy, statins, and 
coronary revascularization is available 
and patients benefit from early treatment, 
fast diagnosis of ACS is essential. On the 
other hand, the importance of early ex-
clusion of ACS is highlighted by the high 
costs and unnecessary anxiety of patients 
having to wait many hours in the emer-
gency department (ED) until ACS is safe-
ly ruled out.
Clinical evaluation of patients 
with suspected ACS
In Germany 11% of all ED admissions hap-
pen because of acute chest pain or other 
symptoms suggestive of ACS [3]. The ma-
jority of these patients will ultimately be 
found not to have ACS. Therefore, the ex-
clusion process has received increased at-
tention. A crucial part is the first evalua-
tion of the patient. Physical examination 
can show signs of hemodynamic instabili-
ty (e.g., tachycardia and hypotension), but 
usually reveals no specific findings. As-
sessment of the patient history is essential 
and should address symptom location, on-
set, character, severity, radiation, alleviat-
ing and exacerbating factors, time course, 
history of similar episodes, and associated 
symptoms, including sweating or dyspnea. 
It should be noted that patients sometimes 
do not refer to their symptoms as “pain” 
but rather as “discomfort” [4]. The ECG 
is considered a vital sign in this group of 
patients and should always be done with-
in the first 10 min [4, 5]. Unfortunately, it 
has a relatively poor sensitivity, and there-
fore safe exclusion requires the combined 
use of clinical assessment, ECG, and car-
diac biomarkers, preferably cardiac tro-
ponin (cTn) [6]. Before discussing the 
relative importance of these three diag-
nostic variables, it is important to high-
light that ACS consists of three different 
pathophysiological entities: ST-elevation 
myocardial infarction (STEMI), which is 
usually caused by a complete occlusion of 
an epicardial coronary artery; non-STE-
MI (NSTEMI), which may be caused by 
a complete obstruction, but more often is 
caused by a high-grade thrombotic coro-
nary stenosis that has already resulted in 
distal embolization and thus cardiomyo-
cyte injury; and unstable angina (UA), 
in which a high-grade coronary stenosis 
is present as well but did not cause distal 
embolization and/or cardiomyocyte inju-
ry. The entities STEMI and NSTEMI are 
summarized as acute myocardial infarc-
tion (AMI) [7]. This distinction has ma-
jor clinical implications, as UA has recent-
ly been identified to be a much more be-
nign disorder with much lower mortality 
rates and probably does not benefit from 
early and aggressive therapy [8].
Cardiac troponins I and T
In combination with symptoms and/or 
ECG changes, CTn is an essential compo-
nent of the definition of AMI and UA [7]. 
The two cardiac troponins T and I are car-
diomyocyte-specific proteins that play an 
essential role in the contraction of cardi-
ac muscle [9]. Their function is to trans-
late the excitation signal into contraction 
of the actin and myosin filaments. As they 
are only expressed in heart muscle cells, 
they are markers with a high specificity 
for myocardial damage [7, 10] and are re-
leased, for example, during AMI, but not 
in conditions representing frequent dif-
ferential diagnoses, such as musculo skel-
etal pain, pleuritis, gastroesophageal re-
flux, pneumonia, or gastritis. As levels 
of cTn are organ- but not disease-specif-
ic, mild elevations in cTn may well be en-
countered in conditions that are associat-
ed with smaller amounts of cardiomyo-
cyte injury, such as heart failure, pulmo-
nary embolism, or aortic dissection [4]. 
The levels detected in peripheral blood 
also allow quantification of the amount of 
cardiomyocyte injury. A major limitation 
of conventional cTn assays is their low 
sensitivity at the time of patient presenta-
tion, which is due to a delayed increase in 
circulating levels, as a significant amount 
of cells must be damaged to reach detect-
able levels. Therefore, serial sampling for 
up to 6–12 h is necessary for safe exclu-
sion of AMI in all patients with suspect-
ed ACS [7]. 
This limitation has now been largely 
overcome by advances in assay technol-
ogy, allowing the precise measurement 
of very low concentrations of cTn. With 
these new high-sensitivity (hs-cTn) as-
says, cTn has become detectable in 50–
90% of healthy patients [11]. This allows 
the definition of a range of normal cTn 
levels within the population and conse-
quently the formulation of a 99th percen-
tile of healthy individuals as the recom-
mended upper reference limit for clinical 
decision making. The use of this upper 
limit of normal has been incorporated in-
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to the Universal Definition of Myocardi-
al Infarction [7]. As a consequence, differ-
entiation between especially NSTEMI and 
UA is more easily possible, as UA usually 
presents with no or only small changes of 
cTn levels not exceeding the 99th percen-
tile [7]. Again, this distinction has major 
implications.
Use of the 99th percentile as the up-
per limit of normal results in the detec-
tion of a considerable number of patients 
with mild elevation in cTn from causes 
other than ACS. These include chron-
ic disorders, such as heart failure, valvu-
lar heart disease, and stable coronary ar-
tery disease, as well as cardiac and noncar-
diac acute disorders with cardiac involve-
ment, such as myocarditis, arrhythmias, 
or severe sepsis with cardiomyocyte in-
jury [4, 12, 13]. Overall, a strategy includ-
ing hs-cTn seems to be the most practical 
and cost-efficient method currently avail-
able for diagnosis and treatment of ACS 
[14]. When dealing with hs-cTn assays, 
there is one caveat: Experts have started 
advocating the reporting of cTn levels in 
nanograms per liter (ng/l) instead of mi-
crograms per liter (μg/l), as was common 
in the last two decades. The new concept 
should limit errors due to the use of the 
decimal point with μg/l. Furthermore, the 
99th percentile is inherently an assay-spe-
cific cut-off, complicating interpretation 
and transfer of findings from one assay to 
another.
Exclusion
Evaluation of patients with suspected ACS 
is time-consuming, resource-intense, and 
contributes to overcrowding of EDs. This 
leads to duplication of effort during shift 
changes, waste of resources, and unfavor-
able outcomes for patients [15, 16]. While 
the use of hs-cTn assays for inclusion of 
AMI is not without challenges, particu-
larly in patients with mild elevation, hs-
cTn might just be the perfect tool for rapid 
and reliable early exclusion of AMI. With 
conventional cTn assays, two consecutive 
measurements within 6–12 h are neces-
sary to safely rule out AMI. Recently, sev-
eral protocols using hs-cTn with or with-
out a clinical risk score and ECG findings 
were derived and validated for more rapid 
exclusion (. Fig. 1). The current Europe-
an Society of Cardiology (ESC) guidelines 
from 2011 [17] propose an algorithm al-
lowing safe exclusion after only 3 h, when 
using hs-cTn assays. The new ESC algo-
rithm also suggests that depending on the 
onset or maximum of acute chest pain, if 
known with certainty, an even earlier ex-
clusion is feasible. An accelerated diag-
nostic protocol incorporating the throm-
bolysis in myocardial infarction (TIMI) 
score, the ECG and cTn levels at 0 h and 
2 h have been found to allow fast and safe 
exclusion in up to 40% of consecutive pa-
tients [18]. To further accelerate the pro-
tocol, we derived and tested an exclusion 
within 1 h, based solely on hs-cTnT val-
ues and absolute change, and were able to 
rule out patients with a very high sensitiv-
ity and a negative predictive value (NPV) 
[19]. This hs-cTnT 1-h algorithm has pro-
spectively been validated in a large inter-
national study (TRAPID-AMI), with the 
main results expected to become avail-
able in the second half of 2014. Another 
strategy to reduce the time to discharge is 
the use of point-of-care cTn assays. While 
clearly reducing the turnaround time, the 
current generation of point-of-care cTn 
assays do not reach the sensitivity offered 
by the hs-cTn assays run on large labora-
tory platforms. This may at least to some 
extent explain the mixed results obtained 
in initial clinical trials [20].
It is important to highlight that we still 
do not have a biomarker accurately indi-
cating myocardial ischemia without car-
diomyocyte injury; therefore, clinical as-
sessment and the ECG remain the key el-
ements for a positive diagnosis of UA. As 
cTn is an integral part of the AMI diagno-
sis, methodologically it is very difficult for 
any other biomarker to provide an incre-
mental value. Only two biomarkers were 
able, at least to some extent, to show a di-
agnostic benefit for the early exclusion of 
AMI: copeptin and heart-type fatty acid 
binding protein (h-FABP).
Copeptin
Arginine vasopressin (AVP) plays an im-
portant role in fluid balance and vascu-
lar tone [21, 22]. It is secreted as a prohor-
mone from the pituitary gland and then 
cleaved from its precursor. The C-termi-
nal part of the provasopressin is called co-
peptin and, from an analytical viewpoint, 
offers a distinct advantage as it is much 
more stable while being secreted in equi-
molar amounts with AVP. Rapid increas-
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Fig. 1 8 The use of hs-cTn assays allows more rapid exclusion and inclusion. 
Inclusion of acute myocardial infarction (AMI) can be made at presentation 
(0 h) in patients with unequivocal ST elevations, at 1 h in patients with el-
evations in cTn in the measurement performed at presentation (analytical 
time is around 1 h in most hospitals), but only at 7 h if the first cTn is nor-
mal and the elevation in cTn becomes apparent only at the second mea-
surement performed after 6 h. Exclusion requires a normal second cTn lev-
el and therefore 7 h. According to the 2011 European Society of Cardiolo-
gy (ESC) guidelines, AMI can be reliably ruled out at 4 h if the hs-cTn assay is 
used. Recent research has indicated that hs-cTn assays may allow even ear-
lier exclusion and inclusion if assay-specific algorithms are used or if applied 
in combination with copeptin. AHA/ACC American Heart Association/Ameri-
can College of Cardiology
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es of copeptin reflect acute endogenous 
stress [23], as caused by stroke, sepsis, or 
AMI [24]. Used in conjunction with con-
ventional cTn assays, measurement of co-
peptin was associated with a substantial 
increase in early diagnostic accuracy, par-
ticularly the NPV for AMI at presenta-
tion. The high sensitivity of a dual-mark-
er strategy (negative hs-cTn and negative 
copeptin) for early exclusion of AMI at 
presentation has been confirmed by sev-
eral prospective observational studies in-
cluding more than 8,000 patients [25]. In 
addition, the safety of this approach has 
recently been confirmed in a multicenter 
randomized controlled study [26].
Heart-type fatty acid 
binding protein
h-FABP is a cytoplasmic carrier protein 
that facilitates transport of long fatty acids 
from the cell membrane to mitochondria 
[27]. As it is small, soluble, and not struc-
turally bound like cTn, it appears in the 
peripheral blood shortly after myocardial 
damage and therefore might contribute to 
early diagnosis of AMI. Nonetheless, re-
cent studies investigating the added value 
of h-FABP on top of hs-cTn failed to show 
a clinically relevant benefit [28, 29]. A re-
maining niche might be patients present-
ing very early after symptom onset. This 
small subset of patients warrants studies 
with both copeptin and h-FABP.
Further and future biomarkers
Additional biomarkers have been tested 
for the evaluation of patients with symp-
toms suggestive of ACS, but a clinical-
ly relevant diagnostic advantage was not 
seen. Some proved to have prognostic val-
ue and will be listed here. The best known 
is B-type natriuretic peptide (BNP) [30, 
31], which is expressed in the cardiomyo-
cytes in response to ventricular wall sheer 
stress or ischemia [32, 33]. Its functions are 
cardioprotective and include mechanisms 
such as a shift of intravascular volume and 
inhibition of sympathetic drive. As an an-
alytical alternative, N-terminal pro-BNP 
(NT-proBNP) or mid-regional pro-ANP 
(MR-proANP) provide similar prognos-
tic, but not meaningful diagnostic, infor-
mation for AMI and/or ACS [34].
An even stronger prognostic value 
than BNP seems to be associated with 
mid-regional pro-adrenomedullin (MR-
proADM) [35, 36], a stable cleavage prod-
uct of the prohormone of ADM.  ADM 
has effects similar to BNP, being a potent 
vasodilator, increasing cardiac output, and 
inducing diuresis and natriuresis [36]. 
Another new biomarker is growth differ-
entiation factor 15 (GDF-15), which is pro-
duced in response to tissue injury, oxida-
tive stress, or inflammation. Its prognostic 
value was shown for STEMI [37] as well as 
NSTEMI [38].
Furthermore, there is a group of bio-
markers associated with plaque rupture, 
such as high-sensitive C-reactive pro-
tein (hs-CRP), myeloperoxidase (MPO), 
myeloid-related protein 8/14 (MRP), and 
pregnancy-associated plasma protein-A 
(PAPP-A). Although AMI is mostly as-
sociated with plaque rupture, this group 
of markers could not show an additional 
diagnostic value for the diagnosis of AMI 
[39].
As a future perspective, advances of 
proteomics might soon allow the identifi-
cation of other potential cardiac biomark-
ers that might provide help in addressing 
the remaining unmet needs in the hs-cTn 
era [40].
Conclusion
hs-cTn is an essential component of the 
evaluation of patients with suspected 
ACS. Used either alone with serial mea-
surements at 1 h, 2 h, or 3 h, or in combi-
nation with a clinical score or copeptin, 
hs-cTn allows the early and safe exclu-
sion of ACS in a substantial number of 
these patients. This will contribute to 
better and faster patient management.
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Abstract
The acute coronary syndrome (ACS) rep-
resents a diagnostic challenge: on the one 
hand patients need to be quickly identified to 
initiate treatment and on the other hand ear-
ly exclusion of patients without ACS is impor-
tant to relieve patient stress as well as over-
crowded emergency departments. A growing 
number of biomarkers are becoming avail-
able to aid physicians with this task. This re-
view gives an overview of the current re-
search concerning early exclusion with an 
emphasis on the clinically most important 
biomarker: cardiac troponin.
Keywords
Biomarkers · Troponin · Acute myocardial 
infarction · Acute coronary syndrome · 
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Kardiale Biomarker für die 
Infarktdiagnose und den 
frühzeitigen Ausschluss eines 
akuten Koronarsyndroms
Zusammenfassung
Das akute Koronarsyndrom (ACS) stellt eine 
diagnostische Herausforderung dar: einer-
seits müssen kranke Pateinten schnell identi-
fiziert werden, um die entsprechende Thera-
pie zu beginnen. Andererseits ist der sichere 
Ausschluss von Patienten ohne ACS ebenfalls 
essenziell, um weder Patienten noch überfüll-
te Notfallstationen zu belasten. Eine wach-
sende Zahl von Biomarkern steht Ärzten als 
Hilfsmittel dazu zur Verfügung. Dieser Über-
sichtsartikel gibt eine Zusammenfassung der 
aktuellen Forschungsarbeiten zum frühze-
itigen Ausschluss des ACS mit einem beson-
deren Fokus auf den klinisch wichtigsten Bio-
marker: kardiales Troponin.
Schlüsselwörter
Biomarker · Troponin · Akuter Herzinfarkt · 
Akutes Koronarsyndrom · Ausschluss
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